An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Cameron Health, Inc. announced today that it has completed enrollment in its pivotal FDA clinical study of the S-ICD System, the world's only completely subcutaneous implantable defibrillator.
Boston Scientific Corporation today announced CE Mark approval and first use in Europe of its Blazer™ Open-Irrigated Catheter, the Company's latest radiofrequency ablation (RFA) catheter designed to treat a variety of arrhythmias such as atrial fibrillation, atrial flutter, ventricular tachycardia and other supraventricular tachycardias. The product is being launched this quarter in select CE Mark countries.
Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.
Global Health Partner: FIRST QUARTER 2011. Revenues increased by 27 percent to SEK 178.9 million.
An invention by Rice University bioengineering students in collaboration with the Texas Heart Institute is geared toward giving immediate second chances to arrhythmia victims headed toward cardiac arrest.
The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.
Novation, the leading health care supply contracting company, announced today the addition of BIOTRONIK (Lake Oswego, OR) to its Cardiac Rhythm Management (CRM) Devices portfolio. This new 30-month agreement represents the first collaboration between the respective organizations.
When a high school athlete drops dead, the rare but fatal condition called "sudden death syndrome" dominates the headlines. For reasons that remain a mystery to scientists, some young athletes - especially young males - begin to experience an unusual heart arrhythmia. With over-exertion, their hearts stop pumping, leading to sudden death.
Johns Hopkins scientists have developed a simplified, cheaper, all-purpose method they say can be used by scientists around the globe to more safely turn blood cells into heart cells. The method is virus-free and produces heart cells that beat with nearly 100 percent efficiency, they claim.
Novation, the leading health care supply contracting company, announced today the addition of St. Jude Medical (St. Paul, MN) to its portfolio of agreements for Cardiac Rhythm Management products.
The sudden death of a young athlete always prompts full media attention, most recently spurring a call for preventative screening methods, including costly electrocardiogram tests for all school-age athletes.
Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.
Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the final results from the PROTECT II study, presented by William O'Neill, M.D., Dean of University of Miami and Principal Investigator of PROTECT II, at the American College of Cardiology's 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.
Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.
A study of nearly 600 patients with severe non-inflammatory respiratory disease has found that a significant percentage also suffered from anaemia, according to the April issue of IJCP, the International Journal of Clinical Practice.
Cardiac experts who fix arrhythmias, which are electrical problems of the heart, must perform complex catheter procedures while the heart is still beating in order to pinpoint where an electrical malfunction is taking place.
BIOTRONIK SE & Co. KG, a leading manufacturer of cardiac devices, announced today that the last chronic heart failure patient was enrolled in IN-TIME at the Schwabing Clinic in Munich, Germany, with principle investigator Professor Stefan Sack, MD.
The Canadian Cardiovascular Society and Canadian Heart Rhythm Society have produced the first-ever comprehensive guidelines on the use of genetic testing in the clinical management of inherited heart rhythm disorders, released in the March/April issue of the Canadian Journal of Cardiology published by Elsevier.
Reducing cardiovascular risk factors like high blood pressure, smoking, diabetes and being overweight could potentially reduce more than half of all cases of atrial fibrillation, according to research reported in Circulation: Journal of the American Heart Association.
Medtronic, Inc. today announced U.S. Food and Drug Administration approval of the Protecta portfolio of implantable cardioverter-defibrillators and cardiac resynchronization therapy-defibrillators.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.